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Autologous tissue grafting for the restoration of oral tissues is limited by
several factors, including the availability of suf®cient donor tissue. One solution
to this problem may be to develop substitute tissue grafts by attaching
disaggregated autologous cells propagated in vitro to scaffolds composed of
natural or synthetic polymers. We have earlier demonstrated that human dental
pulp and gingival ®broblasts (HPF, HGF) adhere to non-woven polyglycolic acid
(PGA) scaffolds, proliferate and produce extracellular matrix in vitro. We now
report that such HPF and HGF adhered to PGA scaffolds survive when
implanted into subcutaneous sites in immuno-compromised mice. The
transplanted cells synthesize and secrete type I collagen, cellular ®bronectin and
may express genes implicated in transducing bone morphogenetic protein
(BMP) signals. Messenger RNA for BMP-2, -4, -7 (OP-1), the BMP type I
receptors Act RI, BMPR-1A and 1B, the type II receptor BMPR-II, and type I
collagen were detected by reverse transcription-polymerase chain reaction (RT-
PCR). These data revealed that three adult human dental pulp and gingival cell
populations, each from individual donors, attached to PGA scaffolds and
cultured for 24 h in vitro, survive implantation and express genes indicative of a
capacity to produce extracellular matrix. The implanted cells may also express
genes associated with responsiveness to BMP-mediated tissue inductive signals.
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Substantial personal and ®nancial costs attend
congenital and acquired loss of oral tissue structure
and function, yet few effective therapeutic regi-
mens to restore this loss are available. However,
the emerging ®eld of tissue engineering comprises
several strategies that address this problem (1).
These include the direct delivery of certain genes,
proteins or cells to the affected tissues. Restoration
of oral tissue structure and function based upon
direct delivery of tissue inductive signaling proteins
such as growth factors (2±5) and the bone
morphogenetic proteins (3, 6±9) is still in develop-
ment. The therapeutic potential of this approach is
substantial but limited by several factors. These
include the production of suf®cient quantities of
biologically active recombinant proteins, the devel-
opment of suitable carriers for these proteins, the
clearance rate of the protein, and the presence of
responsive cell populations in or near the tissues to
be regenerated. Gene therapy by directly introdu-
cing genes, either as naked DNA or recombinant
virus, into tissues is also being developed for bone
formation (10) but may have similar limitations.
Cell-based connective tissue engineering utilizes
cultured cell/scaffold constructs developed in vitro
as connective tissue graft substitutes (1, 11) for
speci®c tissues, including cartilage (12) and bone
(13, 14). These studies used cells cultured from the
speci®c tissues, e.g. cartilage and bone marrow,
targeted for regeneration.
The ultimate clinical utility of a cell-based
approach to oral tissue engineering depends in
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part upon the availability and accessibility of
autologous cells capable of appropriate differentia-
tion and morphogenesis. For the engineering of
oral or dental tissues, autologous cells should be
used to avoid immune rejection reactions or
immunosupressive therapy. The risk/bene®t ratio
of immunosupressive therapy for the restoration of
oral structure and function is not favorable.
Therefore, we seek to determine if cells must be
obtained from the speci®c tissue targeted for
repair, or if cells cultured from self-regenerating
and more easily biopsied tissues, such as gingiva,
can be utilized.
Little is known about the capacity of cells
cultured from oral connective tissues such as the
gingival corium and pulp to effect tissue repair in
vivo. Data exist suggesting that mesenchymal
tissues contain pluripotential stem cells (11)
which are responsive to inductive signals. Bone
morphogenetic proteins (BMP) induce reparative
dentinogenesis when placed on freshly amputated
dental pulps (6, 7), and osteogenesis when placed in
fresh extraction sockets (15, 16) and in surgically
created tissue pockets in monkey gingival corium
(R.B. Rutherford, unpublished observations). This
ectopic osteogenic response appeared to be similar
to exogenous BMP-induced ectopic bone forma-
tion in skin and muscle (17). These data reveal that
both dental pulp and the gingival corium contain
cells responsive to BMP but respond by producing
histologically distinct tissues, reparative dentin or
bone, respectively.
To serve as a source of transplantable cells
capable of regenerating speci®c tissues, donor
tissues must possess populations of cultivable
cells capable of autonomous tissue regeneration
and/or of responding to the speci®c tissue-inductive
stimuli of signaling molecules such as BMP.
Human pulps, cultured pulp and gingival ®bro-
blasts, grown on standard two-dimensional sur-
faces, express mRNA for BMPs and their cognate
receptors (18). These data demonstrate that cells
potentially responsive to BMP signals can be
cultured from dental pulp and gingiva.
The overall goal of this research is to develop
and test oral cell/scaffold constructs as three-
dimensional in vitro models of tissue formation
and as graft substitutes for the repair or regenera-
tion of speci®c oral tissues such as bone and dentin.
Previous studies demonstrate that HPF/PGA
constructs attain, in vitro, a cell population density
approaching mature human pulp tissue in approxi-
mately 45 d (19). Final cellularity is a function of
cell proliferation and decreased construct volume;
the latter thought to result from PGA dissolution
and production of extracellular matrix by the
adherent cells. Microscopic inspection suggested
that these HPF/PGA constructs were probably too
dense to permit suf®cient angiogenesis for survival
in vivo. In contrast human marrow stromal
®broblasts on certain but not all scaffolds tested
form bone in vivo when implanted immediately
after adding the cells to the scaffolds (14). There-
fore, we hypothesized that for optimal restoration
of oral tissue structure and function, the proportion
of cells, extracellular matrix and scaffold will vary
among different cells attached to different scaf-
folds. The experiments reported here initiated
testing this hypothesis by studying the capacity of
HGF and HPF adhered to nonwoven ®brous PGA
scaffolds to survive and function in vivo after 24 h
incubation in vitro.
Material and methods
Human gingival and pulp cells and cell/scaffold
constructs
Cultured human cells were obtained by mincing
fresh adult dental pulp or gingival biopsies
(obtained as surgical waste) from individual
donors and explanting the minced tissue as
described previously (20). Diploid cell cultures
propagated from a single donor (cell strains) were
given the designator human pulp or gingival
®broblast (HPF or HGF) and a unique number.
The cells of each tested strain were harvested,
counted electronically (Coulter Electronics, Hia-
leah, FL, USA) and either frozen for later use (2nd
to 9th passage) or seeded directly onto the
scaffolds. PGA scaffolds measuring 16160.3 cm
were cut from sheets of commercially prepared
standard nonwoven PGA with ®ber diameter of
12 mm, a bulk density of 48 mg/ml at 3 mm thick
(Albany International Research, Mans®eld, MA,
USA) and sterilized by gamma-irradiation. Pre-
liminary experiments determined that 106 cells/
ml stirred in complete media (DMEM, 10%
fetalbovine serum (Hyclone, Provo, UT, USA),
penicillin/streptomycin (100 units/100 mg/ml) at
approximately 60 rpm at 37³C in a humidi®ed
atmosphere of 5% CO2 and 95% air for 24 h
optimized initial cell attachment (B. Buurma,
unpublished observations). Initial cellularity was
quanti®ed by ¯uorometric determination of the
amount of DNA/scaffold (corrected for differences
in scaffold mass). Chemical analyses revealed that
the linear range of the ¯uorometric DNA assay was
from 10±500 ng DNA/ml, the lower limit corre-
sponding to 1,500 cells/ml, and that HGF or HPF
contained 6.61¡1.2 pg DNA/cell; a value consis-
tent with other connective tissue cells (21). PGA
had no effect on the DNA assay. Stirring cell
suspensions at 106cells/ml, 5 ml/cm2 scaffold for
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24 h maximized initial cellularity as measured by
DNA content of the HGF/PGA constructs (a mean
of 2.96103¡1.46102 ng/scaffold, n~10). This was
independent of cell strain and passage number. The
seeded scaffolds were transferred to multi-well
dishes, immersed in fresh media, incubated for 24 h
at 37³C in a humidi®ed atmosphere of 5% CO2 and
95% air to remove non-adherent cells. Some
scaffolds were developed with HPF or HGF
transduced with a recombinant adenovirus,
AdRSVntlacZ (Vector Core Lab., University of
Michigan), that transduces cells with the bacterial
lacZ gene including a nuclear transporter gene (nt)
sequence. This gene transports the b-galactosidase
into the nucleus where it is detected by enzyme
histochemistry. Cells were transduced by incuba-
tion with AdRSVntlacZ for 18±24 h at a multi-
plicity of infection of 100 pfu/cell in media. This
results in a transduction ef®ciency of approxi-
mately 50%. Transduced and nontransduced cells
were attached to PGA scaffolds as described
above. Triplicate constructs comprising 3 strains
each of HPF and HGF (transduced and nontran-
duced) were developed and implanted.
Implantation of cell/scaffold constructs
HPF/PGA, HGF/PGA and PGA control cell/
scaffold constructs were implanted into dermal
pouches created by blunt dissection laterally from a
single dorsal midline incision in immunocompro-
mised mice (N:NIH-bg-nu-xidBR, Charles River,
Wilmington, MA, USA). The wounds were clipped
to obtain primary closure. The implants were
harvested after 3 wk and either immediately ®xed
by immersion in 4% p-formaldehyde or frozen by
immersion in liquid nitrogen for RNA extraction.
All procedures involving animals were conducted
according to protocols approved by the University
of Michigan Committee for the Use and Care of
Animals.
RNA preparation
Total RNA from cell/scaffold constructs was
extracted using the RNAStat-60 method (TEL-
TEST B; Friendswood, TX, USA). Frozen cell/
scaffold constructs were wrapped with clean
aluminum foil, pulverized, and the resultant
powder mechanically homogenized in RNAStat-
60. The homogenate was mixed with 0.1 volume of
chloroform and the phases separated. The RNA
was precipitated from the aqueous phase with
isopronanol at 1:1 (vol:vol) for 15 min at room
temperature or overnight at ±20³C, and quanti®ed
by UV absorbance spectrometry.
RT-PCR
The S-14, BMP and BMPR primers and procedures
for reverse transcriptase-polymerase chain reaction
(RT-PCR) utilized in these experiments were the
same as described previously. The sizes of the
ampl®ed cDNA fragments range from 571 to 698 bp.
Histology and immunocytochemistry
Histologic and immunocytochemical analyses were
performed on constructs ®xed by immersion in
several volumes of fresh 4% p-formaldehyde and
embedded in paraf®n. Freshly sectioned samples
(4±6 mm) were stained alternatively with hematox-
ylin and eosin, or developed for immunocytochem-
istry using rabbit anti-human type I collagen or
anti-human cellular ®bronectin (BioDesign,
Kennebunkport, ME, USA) according to the
Vectastain ABC and DAB substrate kits (Vector
Laboratories, Burlingame, CA, USA). Control
sections were reacted with non-immune serum
replacing the speci®c primary antiserum. Staining
for lac Z expression was performed on fresh 4%
p-formaldehyde ®xed sections using a commercial
kit (Invitrogen, San Diego, CA, USA) according to
the manufacturer's instructions.
Results
Triplicate lacZ-transduced and nontransduced
HGF and HPF/PGA constructs from three inde-
pendent cell strains for each cell type (18 total) and
9 control cell-free/PGA constructs were prepared
and implanted in immuno-de®cient mice. The
initial cellularity was kept constant at approxi-
mately 36103 ng DNA/cm2. An equal number of
HPF and HGF as cell pellets (unattached to PGA)
were also implanted. After 3 wk, ectopic tissue
masses were apparent at the sites of implantation
for all implants except for the human cell pellets
and 67% of the cell-free/PGA scaffolds. Successful
implantation was de®ned as clinically evident grafts
that were vascularized and contained transplanted
human cells.
By 3 wk, new vessels penetrated all HPF (data
not shown) and HGF/PGA implants (Fig. 1A).
Residual PGA ®bers were visible throughout the
implanted tissue. Intact cells appeared in close
association with PGA ®bers as well as distributed
throughout the extracellular matrix that largely
®lled the inter®ber space. To determine if HGF
and HPF survived implantation, cells were tran-
siently transduced with a recombinant adenovirus
(AdRSVntlacZ) which contains a bacterial b-
galactosidase (lacZ) gene. Transduced cells express
the lacZ gene product principally in the nucleus by
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virtue of the nt gene segment which encodes for
a nuclear translocator domain. AdRSVntlacZ
infected HPF/PGA, HGF/PGA and PGA control
grafts were analyzed for the presence of the
transduced lacZ gene. All implants containing in
vitro infected HGF/PGA (Fig. 1B) or HPF/PGA
(data not shown) contained viable transplanted
cells as evidenced by expression of the transduced
bacterial lacZ gene. Implanted mock-infected
HGF/PGA constructs (Fig. 1C) or tissues asso-
ciated with cell-free PGA scaffolds did not express
the lacZ gene (Fig. 1D).
The presence of viable human cells in the
implanted tissues was also demonstrated by RT-
PCR analyses of total RNA for the presence of
human S-14 ribosomal protein speci®c mRNA
(Fig. 2). The PCR primers for human S-14
ribosomal protein, used in these experiments,
amplify different sized cDNA fragments from
mouse and human cDNA. Total RNA from all of
the HGF/PGA constructs cultured for 24 h in vitro,
implanted and grown for 3 wk in vivo contained
human and mouse cell S-14 ribosomal protein
RNA (Fig. 2). Identical results were obtained from
HPF/PGA constructs (data not shown), while the
identi®able cell-free PGA implants did not contain
human speci®c mRNA (Fig. 2).
The implanted human cells also appeared
to secrete extracellular matrix proteins. Cells
Fig. 1. Photomicrographs of noninfected (A), AdRSVntlacZ HGF/PGA (B) mock-infected (C) and cell-free/PGA (D) constructs
after 3 wk in vivo. In panel A, cells and extracellular matrix adhered to and interspersed among the PGA ®bers (arrowhead) are
evident as are vessels (V) that have penetrated the implant. In panel B, cells expresssing the lacZ gene are clearly evident in
implants comprised of AdRSVntlacZ transfected HGF cells. No lacZ expressing cells are evident in mock-infected (C) and cell-free
PGA control implants (D). Sections stained with H & E stain (A), lacZ detection using X-gal substrate (as described in materials
and methods) and counterstained with eosin (B, D). Original magni®cation 630, bar equals 25 mm.
Fig. 2. Implanted HGF/PGA constructs express human S-14
ribosomal protein after 3 wk in vivo. cDNA fragments
generated using primers, derived from the human gene
sequence for S-14 ribosomal protein, in RT-PCR analyses of
total RNA are displayed in an enlarged digitized image of an
ethidium bromide stained DNA gel. 123-bp fragments are
ampli®ed from human RNA; whereas approximately 500-bp
fragments are ampli®ed from mouse RNA. Lane contents were
as follows: 1) mw markers; 2) control containing no DNA
template; 3) cell-free/PGA control; 4) mixture of 7: 1 mouse/
human RNA; 5 & 6) HGF/PGA constructs and 7) unimplanted
HGF/PGA control construct.
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immuno-positive for human cellular ®bronectin
(Fig. 3A) and type I collagen (Fig. 3B) were
adhered to PGA ®bers and distributed within the
ECM. Equivalent sections developed with non-
immune sera were negative (Fig. 3C) as were
sections from cell-free PGA control implants
analyzed for collagen and ®bronectin (Fig. 3D±
F). Taken together, these data indicate that human
gingival and pulp cells, following attachment to
PGA scaffolds and 24 h in culture, survived,
synthesized and secreted extracellular matrix
proteins for at least 3 wk in vivo.
Fig. 3. HGF/PGA implants express human ®bronectin and type I collagen after 3 wk in vivo. Photomicrographs of HGF/PGA
implants developed by immunohistochemistry for human cellular ®bronectin (A), and type I collagen (B) after implantation for
three weeks are displayed. The presence of human ®bronectin and type I collagen coating the PGA ®bers and spanning the inter®ber
spaces is evident in the section developed with speci®c anti-human antibodies, but not in sections developed with control non-
immune sera (C). Human ®bronectin (D) or type I collagen (E) is not evident in cell-free/PGA control implants developed with
speci®c antihuman antibodies or nonspeci®c sera (F). The PGA variably stains in sections developed with both speci®c and
nonspeci®c antisera. Histologic preparation and immunocytochemistry were performed as described in Material and methods.
Original magni®cation 630, bar equals 25 mm.
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Additional evidence of the survival and function
of the implanted human cells is provided by
comparison of the expression of several genes
associated with responsiveness to bone morphoge-
netic proteins (BMP). Total RNA from HGF/PGA
constructs contained mRNA for BMP-2, -4, -7,
BMPR-IA, BMPR-IB, BMPR-II, ActR-I and type
I collagen after attachment and incubation for 24 h
in vitro (data not shown) and after implantation for
3 wk (Fig. 4A). These PCR primers, designed using
the human DNA sequences for these genes
(GenBank), all routinely amplify similar sized
cDNA fragments from mouse and human cDNA
except those for BMP-2. These primers routinely
fail to amplify a BMP-2 cDNA in RT-PCR
analyses of mouse skin total RNA (Gu, unpub-
lished data). The presence of BMP-2 cDNA was
not detected in the PGA control (no attached
human cells) implants (Fig. 4B) or in control mouse
skin samples (data not shown). Similar results were
obtained from identical analyses of HPF/PGA total
RNA (data not shown). These data further support
previous data and reveal that implanted human
cells from three non-transduced strains of HGF
and HPF attached to PGA and cultured for 24 h in
vitro survived in vivo. These cells may express
mRNA for genes required for BMP responsive-
ness.
Discussion
Cell/scaffold constructs; survival and function
Tissue transplantation is currently limited by the
availability of suf®cient donor tissue, donor site
morbidity as well as the varying effectiveness of
available allogenic transplant carrier materials.
Recently, signi®cant advances in tissue transplan-
tation have been made by seeding and propagating
disaggregated cells on synthetic, polymer scaffolds
in vitro permitting the development of biological
tissue substitutes for implantation in vivo (1, 14, 19,
22). These studies demonstrate that variations in
cell type, scaffold materials, and in vitro develop-
ment time affect the proportion of cells, extra-
cellular matrix and scaffold in the constructs and
the capacity to form tissue in vivo. In addition, the
capacity of various scaffold materials to support
the growth of bone in vivo vary (14). This led to our
hypothesis that the optimum proportions of cells,
extracellular matrix and scaffold for successful
implantation vary for each combination.
To initiate testing of this hypothesis, HPF and
HGF/PGA constructs, and cultured in vitro for
24 h, were implanted in vivo. Our data reveal that
upon implantation these HGF and HPF/PGA
constructs became vascularized and retained
viable transplanted cells that synthesized extra-
cellular matrix in vivo. Vessels were distributed
throughout the mass of the implants, and viable
cells were closely associated with the residual PGA
®bers and were interspersed within the extracel-
lular matrix (ECM) which largely ®lled the space
among the polymer ®bers (Fig. 1). We conclude
that these cell populations contain transplanted
human cells, since human transplanted cell-speci®c
gene expression was detected at both the protein
and RNA levels (Figs. 2, 4). The most compelling
evidence is provided by the in vivo expression of
the transduced lac Z gene in the transplanted
tissues. The most plausible explanation for the
speci®c expression of this gene is survival of the
transplanted cells that had been transduced with
the lac Z gene in vitro prior to transplantation. The
detection of human S-14 ribsomal protein RNA
(Fig. 2) and human proteins associated with
extracellular matrix production (Fig. 3) also sup-
ports this conclusion. In addition, total RNA from
the transplanted tissues contained mRNA for BMP
2, 4 and 7, BMPR as well as type 1 collagen. All of
the primers for the human BMP and BMPR genes
of interest in this project, except those for BMP-2,
hybridize to mouse cDNA suf®ciently to support
ampli®cation of similarized sized gene fragments.
Therefore, the presence of ampli®ed BMP-2 in
HGF or HPF/PGA, but not control PGA implants
(Fig 4), reinforces the conclusion that the tissues
contain surviving transplanted human cells.
It appears from the proportion and distribution
Fig. 4. HGF/PGA constructs express type I collagen, BMP
receptor and BMP genes 3 wk after implantation in vivo.
cDNA fragments generated using primers derived from human
gene sequences in RT-PCR analyses of total RNA from HGF/
PGA after 3 wk in vivo (A) and PGA control constructs after
3 wk in vivo (B) are displayed in an enlarged digitized image of
an ethidium bromide stained DNA gel. Lane 1, mw markers
(123, 246, bp etc.); 2, Act R-I; 3, BMPR-IA; 4, BMPR-IB; 5,
BMPR-II; 6, BMP-2; 7. BMP-4; 8, BMP-7; 9, collagen I.
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of cells expressing transduced lac Z (Fig. 1) that the
bulk of the tissue ®lling the space within the PGA
scaffold is of mouse origin. This result is not
surprising since approximately 90% of the volume
of the implanted construct is un®lled space at the
time of implantation. Mouse granulation tissue is
expected to form at a higher initial rate than human
tissue. These data demonstrate that HPF and HGF/
PGA constructs, developed for only 24 h in vitro,
survive and secrete extracellular matrix after
transplantation. However, it appears likely that
more in vitro development time is required to
increase the cell/extracellular matrix to scaffold
ratio to increase proportion of donor tissue in the
site of implantation.
Scaffolds
Other experiments have demonstrated that HPF
fail to adhere to various hydrogels in vitro (23),
revealing that not all synthetic polymers are
suitable scaffolds for these cells. KREBSBACH and
co-workers (14) demonstrated that human and
mouse marrow stromal ®broblasts (MSF), isolated
and passaged in culture, formed bone when
dissaggegated, seeded to scaffolds and implanted
directly in vivo. Interestingly, the osteogenic
potential of the human MSF was related to
the scaffold; varying from none with demineral-
ized bone powder to strong with a collagen-
hydroxyapatite composite (Collagraft StripTM). In
parallel experiments, human foreskin ®broblasts
formed ®brous connective tissue but not bone in
vivo. Whereas these studies did not exhaustively
test the effects of attached cell number and in vitro
development time, the data suggest different
tissue-forming potentials for distinct cell popula-
tions as well as an important role for the type of
scaffold utilized as a cell vehicle.
The role of scaffolds is not clear. In our
experiments, the presence of a scaffold was
necessary since ectopic tissues failed to form at
all sites implanted with cells without scaffold.
However scaffolding alone is not suf®cient to
routinely induce tissue formation because 2/3 of
the control cell-free PGA implants failed to
produce clinically evident tissue masses. Tissue
masses containing human cells were present in 18/
18 of sites implanted with HGF or HPF/PGA
constructs. The reason for the higher frequency of
clinically evident tissues found in experimental
versus control implants is not apparent at this time.
Scaffolds may facilitate the formation of func-
tional tissues by providing a biodegradable vehicle
for the delivery to and retention of organized cell-
matrix constructs in a speci®c in vivo site. Synthetic
scaffold materials, such as polyglycolic acid, have
several potential advantages, including: 1) repro-
ducible synthesis; and 2) control of important
mechanical and chemical variables such as shape,
size and pore dimensions as well as scaffold
composition, and rate of biodegradablity. Polymers
that degrade to molecules easily eliminated from
the body are also an advantage. Problems inherent
with polyacids include the acidi®cation of the
environment upon dissolution, however cartilage
has been formed in vivo from cartilage cell/
polyacid constructs (24).
Source of cells for regeneration of speci®c tissues
The source of cells for seeding the synthetic
scaffolds is an important early practical considera-
tion in the development of oral transplant sub-
stitutes. In the foreseeable future, cell-based
therapy for the regeneration of oral tissues
should utilize autologous cells. The risks of
immunosuppresive therapy to protect from allo-
graft or xenograft rejection outweigh the bene®ts
of oral tissue regeneration. Ideally, these cells
should be easily obtained on an out-patient basis
and with minimal donor site morbidity, e.g., a small
gingival versus bone marrow biopsy. The tissues
should contain cells capable, upon implantation, of
producing a functional adult tissue either autono-
mously, by genetic modi®cation, or in response to
appropriate exogenous inductive stimuli (11). Of
interest in this regard is the fact that bone
morphogenetic proteins (BMP) induce both
intra- and extraskeletal bone formation (25) and
reparative dentinogenesis when placed on dental
pulps (6, 7). In addition, ectopic bone forms when
BMP-7 is placed in surgically created connective
tissue pockets in monkey gingiva (Rutherford,
unpublished observations). This response appeared
similar to BMP-induced ectopic bone formation in
skin and muscle (17, 26), except that bone formed
without a cartilage intermediate. These data
suggest that gingival and dental pulp connective
tissues both contain cells responsive to BMP but
respond by producing histologically distinct tissues,
bone and reparative dentin, respectively (27).
Previous studies (18) and the data contained
herein suggest that populations of cells cultured
from these tissue contain cells which express type I
and II BMP receptors proposed to mediate BMP
inductive signals (for reviews see (28). These data
suggest that in the likely event that HPF and HGF/
scaffold constructs produce ®brous connective
tissue in vivo, they contain BMP-responsive
populations capable of forming speci®c minera-
lized connective tissues upon exposure to the
appropriate BMP either in vitro or in vivo.
Experiments testing these ideas are in progress.
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